Product Description: Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Burgess G, et, al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018 Sep;35:67-75.
CAS Number: 2043952-59-4
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related